ERp18 regulates the activation of ATF6α during the unfolded protein response by Oka, Ojore B.V. et al.
Article
ERp18 regulates activation of ATF6a during
unfolded protein response
Ojore BV Oka1 , Marcel van Lith1, Jana Rudolf2, Wanida Tungkum1, Marie Anne Pringle1 &
Neil J Bulleid1,*
Abstract
Activation of the ATF6a signaling pathway is initiated by traf-
ficking of ATF6a from the ER to the Golgi apparatus. Its subsequent
proteolysis releases a transcription factor that translocates to the
nucleus causing downstream gene activation. How ER retention,
Golgi trafficking, and proteolysis of ATF6a are regulated and
whether additional protein partners are required for its localiza-
tion and processing remain unresolved. Here, we show that ER-
resident oxidoreductase ERp18 associates with ATF6a following ER
stress and plays a key role in both trafficking and activation of
ATF6a. We find that ERp18 depletion attenuates the ATF6a stress
response. Paradoxically, ER stress accelerates trafficking of ATF6a
to the Golgi in ERp18-depleted cells. However, the translocated
ATF6a becomes aberrantly processed preventing release of the
soluble transcription factor. Hence, we demonstrate that ERp18
monitors ATF6a ER quality control to ensure optimal processing
following trafficking to the Golgi.
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Introduction
The cellular response to the presence of misfolded proteins within
the endoplasmic reticulum (ER) is collectively termed the unfolded
protein response (UPR; Ron & Walter, 2007). This stress response
involves both translational and transcriptional programs coordi-
nated mainly by three transmembrane transducers localized to the
ER: Ire1a, PERK, and ATF6a (Walter & Ron, 2011). The transla-
tional program activated by PERK leads to the attenuation of trans-
lation following phosphorylation of eIF2a (Lu et al, 2004), whereas
activation of Ire1a leads to the processing of unspliced XBP1 mRNA.
This processing generates spliced transcripts that are translated to a
transcription factor, which upregulates the expression of proteins
involved in ER protein folding, ER-associated degradation (ERAD),
and lipid biogenesis. Ire1a activity also leads to the degradation of
specific mRNAs (Hollien et al, 2009). All transducers activate tran-
scriptional programs that lead to the upregulation of genes coding
for proteins important for ER expansion, protein folding, and
protein degradation (Travers et al, 2000; Okada et al, 2002; Lu
et al, 2004). The consequence of these programs is either recovery
from the cell stress or, if the stress persists, cell death (Walter &
Ron, 2011).
ATF6 exists as two isoforms, a and b (Haze et al, 2001), with
ATF6a being predominant (Thuerauf et al, 2004) and the focus of
this study. ATF6a is normally resident within the ER; however, after
ER stress, it traffics to the Golgi apparatus. Here, it is cleaved
sequentially by site-1 protease (S1P) and site-2 protease (S2P) to
release a soluble bZIP transcription factor, ATF6-N (Ye et al, 2000).
ATF6-N translocates to the nucleus where it binds to ER stress-
responsive elements (ERSEs) in the promoters of UPR genes to bring
about its downstream effects (Yamamoto et al, 2004; Adachi et al,
2008). Regulation of activation is afforded by ATF6a retention in the
ER and by S1P/S2P being located in the Golgi. Localization of
ATF6a is critical to the process of activation and is thought to
involve binding partners that release the ER retention of ATF6a
(Shen et al, 2002; Higa et al, 2014) or bind and recruit ATF6a to
COPII-coated vesicles following stress (Lynch et al, 2012). It is also
thought that the oligomeric state of ATF6a is important in regulating
trafficking (Nadanaka et al, 2007). The ATF6a lumenal domain
contains two cysteine residues that can form either intra- or inter-
chain disulfides. ATF6a in unstressed cells exists as a mixture of
disulfide-linked oligomers and monomers. Upon stress, the inter-
chain and intrachain disulfides are reduced giving rise to the sugges-
tion that only the reduced monomeric form exits the ER to the Golgi
(Nadanaka et al, 2007). In addition, there is evidence that the glyco-
sylation status of ATF6a can influence the trafficking of ATF6a as
the hypoglycosylated protein is transported more rapidly than glyco-
sylated ATF6a (Hong et al, 2004a).
The lumenal domain of ATF6a plays a critical role in regulating
ATF6a trafficking. It is both necessary and sufficient to allow ER
retention and release following stress (Chen et al, 2002; Sato et al,
2011), suggesting that the factors or signals influencing cellular
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localization reside within this domain. Distinct regions confer bind-
ing to the ER-localized Hsp70 homologue BiP and act as Golgi-locali-
zation sequences (Shen et al, 2002). Binding of BiP to these regions
could mask localization signals, which only become accessible after
BiP dissociation (Shen & Prywes, 2005). What regulates BiP binding
is not known, but competition for binding to misfolded proteins
could occur (Schindler & Schekman, 2009). However, BiP binding to
ATF6a is relatively stable and does not appear to be regulated by
ATP arguing against a simple competition mechanism (Shen et al,
2005). Other proteins shown to bind to ATF6a that regulate ER-to-
Golgi trafficking include thrombospondin 4, which promotes its
nuclear shuttling in cardiomyocytes (Lynch et al, 2012), and PDIR,
an ER oxidoreductase which modulates packaging of ATF6a into
COPII-coated vesicles (Higa et al, 2014). While we know the identity
of some of the proteins that associate with ATF6a that may prevent
or promote trafficking, what influences their association/dissocia-
tion remains unknown.
To evaluate the regulation of trafficking of ATF6a, we took an
unbiased approach to identify ER proteins interacting with its lume-
nal domain in normal and stressed conditions. From the list of inter-
actors, we identify an ER oxidoreductase, ERp18, that associates
with ATF6a only after ER stress. Further characterization of the role
of ERp18 in ATF6a activation reveals that it regulates ER exit and in
doing so optimizes cleavage by S1P/S2P in the Golgi. These results
uncover an unexpected layer of control over the activation of ATF6a
at the level of Golgi processing with only a specific form of ATF6a
being processed correctly to release soluble transcription factor.
Results
ERp18 only associates with ATF6 following ER stress
To understand more fully the process of ATF6a activation, we
created a stable cell line expressing epitope-tagged ATF6a (Fig 1A)
and confirmed its expression and ER location by immunofluores-
cence (Fig 1B). We evaluated the proteins interacting with ATF6a
before or after ER stress generated by thapsigargin-dependent
calcium depletion (Li et al, 1992). To ensure we captured weakly
interacting proteins and to minimize non-specific binders, we added
an amine-specific thiol-cleavable cross-linking agent, immunoiso-
lated ATF6a complexes, and eluted interacting proteins with the
reducing agent DTT. Eluted proteins were digested with trypsin and
the peptides identified by mass spectrometry. The experiment was
carried out three times, and the proteins consistently observed are
listed along with the % coverage and exponentially modified
protein abundance index (emPAI) scores from a representative
experiment (Table 1). None of these proteins were present in
control samples from untransfected HEK293 cells. The formation of
ATF6a complexes with several of the proteins identified was con-
firmed by their immunoisolation with the V5 antibody and detection
by Western blot (Fig 1C). RCN1 was transiently transfected into
cells for this experiment as our RCN1 antibody did not detect
endogenous protein in HEK293 cells. The interactions were specific
to ATF6a as the signals were much lower or not present in its
absence. The presence of Grp170 in the immunoisolate from
untransfected cells is likely due to non-specific binding to the
agarose beads.
The list of ATF6a interacting proteins is dominated by ER-resi-
dent folding factors including chaperone proteins and folding
enzymes such as BiP, Grp94, and members of the protein disulfide
isomerase (PDI) family. In addition, proteins involved in glycopro-
tein quality control such as calreticulin and glucosidase II were
identified along with members of the CREC family of calcium-
binding proteins, reticulocalbin (1 and 2) and calumenin (Honore,
2009). Some changes to the ATF6a interactome occurred following
ER stress which include the dissociation of the CREC family
members as well as Grp170 and glucosidase II. This result is
expected as the ER stress was caused by calcium depletion and all
of these proteins are calcium-binding proteins which could regulate
their interaction with ATF6a. Absent from the list of interactors
was PDIR and thrombospondin 4, which have previously been
shown to interact with ATF6a (Lynch et al, 2012; Higa et al, 2014).
An interaction between endogenous PDIR and ATF6a before and
after ER stress was observed by Western blotting after immunoiso-
lation of ATF6a (Fig 1D). Endogenous thrombospondin 4 expres-
sion in HEK293 cells was below the level of detection by Western
blot, but an interaction with ATF6a was observed before and after
ER stress following co-expression of thrombospondin 4 with ATF6a
(Fig 1D).
The PDI family member ERp18 was found to associate with
ATF6a only after ER stress. This protein has a single thioredoxin
domain and has been shown previously to have thiol-disulfide
oxidase and isomerase activity as well as protecting cells against
prolonged ER stress (Alanen et al, 2003; Jeong et al, 2008). We con-
firmed the mass spectrometry result by demonstrating an interaction
between ERp18 and ATF6a using an immunoblotting approach
(Fig 1D). We detected ERp18 in ATF6a immunoisolated material in
unstressed cells, the amount of which increased following ER stress
(Fig 1D). Having shown that ERp18 interacts with ATF6a, we
decided to evaluate the role of this protein and other PDIs during
the activation process.
ERp18 is catalytically active toward ATF6a during ER stress
We expressed substrate-trapping mutants of various V5-tagged PDI
family members in the ATF6a-expressing stable cell line to indicate
which PDIs could catalyze disulfide reduction. Mutant PDIs where
the active site was converted from CXXC to CXXA were used to trap
substrates in covalent complexes with the enzyme (Jessop et al,
2007, 2009; Zito et al, 2010; Oka et al, 2013). The formation of a
mixed disulfide between enzyme and substrate indicates that the
first step in catalysis can occur (Walker et al, 1996). We chose the
catalytic PDIs identified as interacting with ATF6a in this study (P5,
ERp72, ERp57, PDI, and ERp18) or by others (PDIR; Higa et al,
2014) as well as ERp46 and TMX1 which had not been shown
previously to interact. When ATF6a was immunoisolated with
anti-ATF6a, separated under non-reducing conditions, and
immunoblotted with anti-HA, the resulting banding pattern indi-
cated the presence of ATF6a monomers (M), dimers (D), and oligo-
mers (O) as previously described (Nadanaka et al, 2007; Fig 2A,
lane 1). In addition, clearly defined mixed disulfides were observed
between ATF6a and ERp18, ERp57, and PDIR as indicated by the
presence of additional bands in the transfected cells that are absent
in the untransfected cells (Fig 2A, lanes 2–9, indicated with an
arrow). No mixed disulfides were observed with PDI itself, ERp46,
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ERp72, P5, or TMX1. As expected, no mixed disulfides with PDIs
were observed with a mutant ATF6a (DM) that does not contain
any cysteines within its ER lumenal domain (Fig 2B). Our results
demonstrate that under non-stressed conditions, a subset of PDIs
including ERp18 can act as reductases toward ATF6a.
To determine the consequence of ER stress on the ability of the
PDIs to catalyze reduction of ATF6a, we co-expressed PDI
substrate-trapping mutants with an S1P cleavage site mutant of
ATF6a that is not processed in the Golgi (Ye et al, 2000). We
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presence of thapsigargin, tunicamycin, or MG132 to provide three
alternative mechanisms to induce ER stress: calcium depletion,
glycosylation, and proteasome inhibition, respectively. Under non-
stressed conditions, very similar patterns of mixed disulfides were
observed following immunoisolation of the S1P cleavage site
mutant of ATF6a and immunoblotting with anti-HA as seen with
the wild-type protein (cf. Figs 2A and 3A, lanes 1, 3, and 5). Under
stressed conditions, the mixed disulfides between ERp57 or PDIR
and ATF6a were either abolished or greatly diminished irrespective
of the ER stressor (Fig 3A–C, lanes 4 and 6). In contrast, of the two
major mixed disulfides between ERp18 and ATF6a, one at
~200 kDa was lost whereas the second at ~150 kDa persisted
following ER stress (lane 2). Note the additional products seen
following tunicamycin or MG132 treatment indicated with ** that
are likely hypoglycosylated ATF6a. In all samples, we also noted a
product at approximately 70 kDa that we designated ATF6-P which
was prominent when we expressed the S1P mutant of ATF6a. This
product will be discussed in more detail below but is likely to be
the same as that seen previously when ATF6a was expressed in the
presence of an S1P inhibitor (Ye et al, 2000; Gallagher et al, 2016).
◀ Figure 1. Validation of ATF6 partner proteins.A Schematic of the ATF6a constructs used in this study. The N-terminus of ATF6a is tagged with a HA epitope or GFP as indicated. The C-terminus is V5-epitope-tagged.
The region N-terminal to the transmembrane domain is localized in the cytosol, whereas the region C-terminal is localized to the ER (lumenal domain). The positions
of the cysteine residues and mutations are as indicated as well as the S1P cleavage site mutation (R415A/R416A). TAD: transactivation domain.
B Immunofluorescence microscopy of HEK293T exogenously expressing ATF6a-V5 tagged. Cells were fixed and stained with anti-calnexin (green) or anti-V5 (red). An
overlay of the cells is presented in the third panel. Bar = 10 lm.
C Whole-cell lysates from HEK293T cells, with or without stable expression of ATF6a (as indicated), were immunoisolated with mouse anti-V5. RCN1 was transiently
transfected into both cell lines in the experiment depicted in panel 3. Immunoisolated material was separated by SDS–PAGE under reducing conditions followed by
Western blotting to determine the co-isolation of ER proteins with ATF6a. Ig-HC (anti-BiP blot) indicates immunoglobulin heavy chains.
D Whole-cell lysates from HEK293T cells stably expressing ATF6a were either untreated () or treated (+) with 5 lM thapsigargin (TG) for 1 h. THBS4 was transiently
transfected into cells in the experiment depicted in panel 2. ATF6a was immunoisolated with either anti-V5 (panels 1 and 3) or anti-HA (panel 2). For the experiment
in panel 3, the cells were cross-linked prior to immunoisolation. Samples were separated by SDS–PAGE under reducing conditions followed by Western blots to
determine co-isolation of endogenous PDIR, ERp18, or exogenously expressed THBS4 with ATF6a. HC indicates immunoglobulin heavy chain.
Source data are available online for this figure.
Table 1. Proteins cross-linked to ATF6 before and after treatment with thapsigargin.
Gene Protein
ATF6 ATF6 + Thapsigargin
% coverage emPAI % coverage emPAI
ATF6A ATF6 6 0.14 6 0.21
HSPA5 BiP 41 2.94 42 4.12
ENPL Grp94 29 0.98 26 0.58
HYOU1 Grp170 3 0.04 0 0
PDIA6 P5 34 1.04 36 1.26
PDIA4 ERp72 39 2.01 37 0.79
PDIA3 ERp57 31 1.19 26 0.69
PDIA1 PDI 14 0.18 26 0.18
ERP29 ERp29 20 0.38 11 0.38
TXNDC12 ERp18 0 0 13 0.28
ERO1A ero1 6 0.11 6 0.11
PRDX4 peroxiredoxin 4 9 0.17 16 0.17
CALR3 calreticulin 17 0.1 0 0
RCN1 reticulocalbin 1 10 0.13 0 0
RCN2 reticulocalbin 2 5 0.14 0 0
CALU calumenin 10 0.14 6 0.14
PPIB cyclophilin B 30 0.86 32 0.86
PRKCSH glucosidase 2 subunit beta 7 0.08 6 0
VCP VCP 3 0.05 10 0.11
UTS2R urotensin-2 isoform b 6 0.38 6 0.38
The table shows percent coverage and emPAI values from a representative experiment. ATF6 + Thapsigargin indicates cells treated with 5 lM thapsigargin for
1 h before cross-linking. Experiment was carried out at least three times.
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The presence of each PDI in a mixed disulfide with ATF6a was veri-
fied by reprobing the Western blots with antibodies to the PDIs
(Fig 3D). These results with the substrate-trapping mutants demon-
strate that ERp18 forms mixed disulfides with ATF6a even after ER
stress.
The presence of mixed disulfides would indicate that either an
intra- or interchain disulfide within the lumenal domain of ATF6a is
reduced by the substrate-trapping mutant of ERp18. To investigate
this further, we created mutants of ATF6a that had one of the
cysteines within the lumenal domain converted to alanine. Single
mixed-disulfide species were seen with either cysteine mutant in the
absence of ER stress (Fig 4A, lanes 3 and 5), indicating that ERp18
reduces C467 or C618 that has formed an interchain disulfide or has
become glutathionylated. Interestingly, the mixed disulfide to the
C467A mutant was sensitive to ER stress whereas the mixed disul-
fide to the C618A mutant was not (lanes 4 and 6). These results
indicate that interchain disulfides present in the ATF6a lumenal
domain can be reduced by ERp18 during and after ER stress and that
the mixed disulfide that persists following stress is via the C467
cysteine.
The mobility of the mixed disulfides was different between the
cysteine mutants. A ~130-kDa species was formed with the C467A
mutant and a ~150-kDa species with the C618A mutant. The mobil-
ity of the interchain disulfide-bonded ATF6a was also different
between the two mutants, consistent with previously published
data (Nadanaka et al, 2007). These mobility differences could
reflect different hydrodynamic volumes of the denatured mixed
disulfides or be due to additional protein(s) associating with the
C618A mutant of ATF6a. To identify additional interacting proteins,
we expressed a GFP-tagged S1P cleavage site mutant ATF6a with or
without the C618A mutation (Fig 1A). Cells were co-transfected
with the substrate-trapping mutant of ERp18, and ATF6a complexes
were affinity-purified using GFP-Trap. When the isolated complexes
were separated by SDS–PAGE under non-reducing conditions and
silver-stained, the presence of both interchain disulfide-bonded
ATF6a and the mixed disulfides was observed (Fig 4B). These
complexes were analyzed following trypsin digestion and mass
spectrometry. No additional protein to ATF6a was present in the
slowest migrating band labeled oligomer (O), and only ATF6 and
ERp18 were present in the mixed disulfides indicated with arrows
(Fig 4B, lanes 2 and 3). The experiment was repeated several times
with the same result. We suggest that the differences in mobility
seen for both the interchain disulfide-bonded ATF6a and the mixed
disulfides are unlikely to be due to additional proteins interacting
with the C618A mutant of ATF6a. Hence, the differences in the
disulfide-bonding patterns may be due to a difference in hydrody-
namic volume after protein denaturation. The two interchain
disulfide-bonded species referred to as dimer and oligomer in the
wild-type protein are likely to both be dimers which have different
electrophoretic mobility due to the disulfide forming between C467
(slower mobility) or C618 (faster mobility). A cartoon summarizing
our interpretation of the mixed disulfides between ATF6a and
A B
Figure 2. PDI family substrate-trapping mutants form mixed-disulfide complexes with ATF6.
A HEK293T cells stably expressing ATF6a were either left untransfected (UT) or transfected with substrate-trapping mutants of PDI oxidoreductases. ATF6a was
immunoisolated from cell lysates with mouse anti-ATF6a and separated by SDS–PAGE under non-reducing conditions and ATF6a detected by Western blotting using
rabbit anti-HA. Blots confirm mixed-disulfide complexes between ATF6a and ERp18, ERp57, and PDIR indicated with arrows (lanes 2, 4, and 5). M, D, and O refer to
ATF6a monomer, dimer, and oligomer, respectively.
B Whole-cell lysates of HEK293T cells expressing an ATF6a mutant containing cysteine-to-alanine mutations in the lumenal domain (ATF6 DM) were transfected with
PDI substrate-trapping mutants. ATF6a was immunoisolated with mouse anti-ATF6a and separated by SDS–PAGE under non-reducing conditions and ATF6a detected
with rabbit anti-HA.
Source data are available online for this figure.
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ERp18 and the potential ATF6a disulfide-bonded dimers is shown
in Fig 4C.
Deletion of ERp18 attenuates the ATF6a stress response
To determine the function of ERp18 during ATF6a activation, we
created an ERp18 KO cell line (Fig 5A). To evaluate whether ERp18
acts during the initial folding of ATF6a, we carried out a pulse-chase
experiment (Fig EV1). No difference in the kinetics of appearance of
the interchain disulfide-bonded forms of ATF6a was observed
between the wild-type and KO cells. This result, together with the
observation that ERp18 is recruited to ATF6a following activation,
suggests that its role is not to assist with the initial folding of the
lumenal domain.
Next, we evaluated the mRNA levels of known UPR-target genes
in the ERp18 KO cell, comparing levels with those in wild-type cells
before or after treatment with thapsigargin as an inducer of ER
stress. No difference in expression of UPR-target genes was seen in
the absence of ER stress (Fig 5B); however, the induction of BiP
mRNA was dramatically attenuated in the KO cells following ER
stress whereas other UPR-target gene induction was unaffected
(Fig 5C). BiP and ERp72 are known targets for ATF6a as well as
other pathways, whereas Grp94 is a target for the ATF6a and Ire1




Figure 3. ER stress modulates ATF6a–PDI mixed-disulfide complexes.
A–D HEK293T cells were co-transfected with ATF6a S1P and PDI substrate-trapping mutants and either left untreated () or treated (+) for 1 h with 5 lM TG (A),
5 lg/ml tunicamycin (B), or 20 lM MG132 (C) to induce ER stress. ATF6a was immunoisolated from cell lysates with mouse anti-ATF6a and separated by SDS–PAGE
under non-reducing conditions and ATF6a detected by Western blotting using rabbit anti-HA. Blots indicate that mixed-disulfide complexes between ATF6a and
PDI enzymes are regulated by ER stress. M, D, and O refer to ATF6a monomer, dimer, and oligomer, respectively. Samples from (A) were rerun and probed with
anti-sera raised against respective PDI enzymes as indicated (D). * indicates positions of the ATF6a–PDI enzyme mixed-disulfide complexes. ** indicates
hypoglycosylated ATF6a. Data shown are representative of three independent experiments.
Source data are available online for this figure.
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are targets for the PERK pathway (Adamson et al, 2016). We also
determined the levels of protein expression following UPR induc-
tion. We observed an attenuation of BiP protein induction in the
ERp18 KO cells as well as the attenuation of induction of ERp72
(Fig 5D–G). These results indicate that the ATF6 pathway in the




Figure 4. ATF6a C467 forms a stable mixed-disulfide complex with the ERp18 substrate-trapping mutant.
A HEK293T cells were co-transfected with the ERp18 substrate-trapping mutant and the indicated ATF6a constructs. Cell were allowed to recover for 24 h post-
transfection before being either left untreated () or treated (+) for 1 h with 5 lM TG to induce ER stress. ATF6a was immunoisolated from cell lysates with mouse
anti-ATF6a and separated by SDS–PAGE under non-reducing conditions and ATF6a detected by Western blotting using rabbit anti-HA. The blot confirms that ATF6a
C618A forms a stable complex with ERp18 trapping mutant following ER stress. M, D, and O refer to ATF6 monomer, dimer, and oligomer, respectively. * indicates
positions of the ATF6–ERp18 mixed-disulfide complexes.
B HEK293T cells were co-transfected with GFP-ATF6a and ERp18 trapping mutant constructs as indicated. GFP-ATF6a complexes were immunoisolated using GFP-Trap.
Immunoisolated material was separated by SDS–PAGE under non-reducing conditions and silver-stained to detect ATF6a disulfide-linked complexes. MS analyses
confirmed that protein bands indicated by black arrows are a complex comprising ATF6a and ERp18, while bands marked as monomer (M) and oligomer (O) contain
ATF6a only.
C Cartoon depicting the presumed composition of the ATF6a disulfide-linked complexes and dimers indicating their respective apparent molecular weight.
Source data are available online for this figure.
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To verify that the attenuation of the ATF6 pathway was due to
the ERp18 KO, we evaluated the consequence of restoring ERp18
expression. For these experiments, we transfected ERp18 into the
KO cell line and evaluated the induction of BiP or ERp72 using
thapsigargin (Fig 5E and G). Expression of ERp18 reversed the
attenuation of BiP or ERp72 induction, demonstrating that the KO





Figure 5. ERp18 knockout downregulates the transcription and translation of ATF6a target genes during ER stress.
A CRISPR/Cas9-based knockout of ERp18 in HEK293T cells expressing ATF6a. ERp18 levels in control (WT) and knockout (KO) cells were detected with an antibody to
ERp18.
B qPCR analysis of UPR-target genes in the absence of ER stress. Wild-type and ERp18 knockout HEK293T cells were untreated prior to isolation of mRNA for qPCR
analysis. mRNA levels for Grp78, Grp94, ATF6a, ATF4, XBP1s (spliced form of XBP1), and ERp72 were normalized to GAPDH and then ERp18 KO levels compared to wild
type. Error bars represent  standard deviation for three independent experiments.
C qPCR analysis of UPR-target genes following ER stress. Wild-type and ERp18 knockout HEK293T cells were treated with 1 lM TG for approximately 16 h prior to
isolation of mRNA for qPCR analysis. mRNA levels for Grp78, Grp94, ATF6a, ATF4, XBP1s (spliced form of XBP1), and ERp72 were normalized to GAPDH and then ERp18
KO levels compared to wild-type controls. Error bars represent  standard deviation for three independent experiments.
D Levels of BiP protein in wild-type or ERp18 KO cells before and after ER stress induction with thapsigargin (TG). Panel 1 compares wild-type and ERp18 KO cells as
indicated. Panel 2 compares ERp18 wild-type cells to ERp18 KO cells that have been transfected with ERp18 (RV).
E Normalized BiP levels from (D) were quantified. Error bars represent  standard deviation for three independent experiments.
F Levels of ERp72 protein in wild-type or ERp18 KO cells before and after ER stress induction with thapsigargin (TG). Panel 1 compares wild-type and ERp18 KO cells as
indicated. Panel 2 compares ERp18 wild-type cells to ERp18 KO cells that have been transfected with ERp18 (RV).
G Normalized ERp72 levels from (F) were quantified. Error bars represent  standard deviation for three independent experiments.
Source data are available online for this figure.
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The absence of ERp18 results in an additional ATF6a
cleavage product
To evaluate further the role of ERp18 in ATF6a activation, we deter-
mined the processing events that occur following ER stress
comparing the wild-type to the ERp18 KO cells. We separated
membrane and nuclear-associated fractions to indicate the location
of processed ATF6a (Gallagher et al, 2016). Cells were treated for
up to 4 h with thapsigargin. In the absence of ER stress, a prominent




Figure 6. Deletion of ERp18 regulates cleavage of ATF6a.
A, B Wild-type and ERp18 KO cells stably expressing ATF6a were treated with 5 lM TG for the indicated times. Cells were then subject to differential centrifugation to
obtain membrane (A) and nuclear fractions (B) which were separated by SDS–PAGE under reducing conditions and analyzed by Western blotting for ATF6a. The
positions of full-length ATF6a (ATF6-FL), cleaved membrane-associated ATF6a (ATF6-P), and nuclear-translocated S2P-cleaved ATF6a (ATF6-N) are as indicated.
HDAC2 was used as a nuclear marker. Data shown are representative of two independent experiments.
C ATF6a was immunoisolated from wild-type or ERp18 KO cells expressing ATF6a. Samples were separated by SDS–PAGE, and ATF6a was detected by Western
blotting. HC indicates immunoglobulin heavy chains.
D, E Blots of membrane and nuclear fractions respectively from ERp18 KO cells overexpressing ATF6a, either untreated () or treated (+) with 30 lM PF429242 (S1P
inhibitor) prior to and following induction of ER stress with 10 mM DTT. The positions of ATF6-P, ATF6-M, and ATF6-N are as indicated. The unprocessed ER-
localized ATF6a (designated ER) and the O-linked glycan-modified Golgi-translocated ATF6a (designated G) are indicated. HDAC2 was included as a nuclear marker.
The blots in (D and E) confirm that ATF6-P is produced independently of S1P and also the absence of ATF6a processing to ATF6-N in the presence of the S1P
inhibitor.
Source data are available online for this figure.
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observed in the KO cells (Fig 6A and B, lane 5). This cleavage
product was also seen in wild-type cells but to a much lesser extent
(lane 1). When an immunoisolation of ATF6a was carried out
followed by a Western blot, the presence of ATF6-P was more clearly
observed in wild-type cells (Fig 6C). ATF6-P was also observed when
the S1P cleavage mutant of ATF6a was expressed (Fig 3A–C). Follow-
ing thapsigargin treatment, additional faster-migrating products were
observed consistent with S1P and then S2P cleavage (Fig 6A, lane 2;
Fig 6B, lanes 2, 3, 6, and 7). The fastest migrating species was only
observed in the nuclear fraction, indicating that it corresponds to
ATF6-N. In the wild-type cells, the S1P product (ATF6-M), which
migrates between ATF6-P and ATF6-N, is maximally observed in the
membrane fraction at 1 h with the ATF6-N product appearing at the
same time in the nuclear fraction. Both cleavage products are dimin-
ished after 4 h consistent with previous observations that ATF6-N is
rapidly degraded following activation (Hong et al, 2004b). ATF6-P in
the KO cells persisted in the membrane fraction throughout the time
course. These results indicate that a consequence of ERp18 KO is the
cleavage of ATF6a in the absence of stress.
The cleavage of ATF6a in the absence of ER stress could be due
to its trafficking to the Golgi and subsequent cleavage by S1P or an
alternative protease. We saw no reduction in intensity of ATF6-P in
the membrane fraction after cells were incubated in the presence of
an S1P inhibitor (Fig 6D, lanes 1 and 2). The S1P inhibitor was
functional as combined treatment with DTT resulted in the buildup
of a slower migrating full-length ATF6a that has previously been
reported to be the result of O-linked glycan modification in the Golgi
(lane 4; Ye et al, 2000; Shen et al, 2002). In addition, treatment with
the S1P inhibitor blocked the appearance of ATF6-N in the nuclear
fraction following DTT activation (Fig 6E, lanes 3 and 4). These
results suggest that the proteolytic processing of ATF6a observed in
ERp18 KO cells in the absence of ER stress is not caused by the S1P.
To determine where within the cell the cleavage of ATF6a to
form ATF6-P takes place, we made use of a naturally occurring
ATF6a mutant that has been shown previously to result in a block
in ER-to-Golgi trafficking (Chiang et al, 2017). Patients carrying a
[D564G] mutation within the ATF6a lumenal domain suffer from a
heritable blinding disease called achromatopsia. We created a cell
line stably expressing ATF6a [D564G] and verified its lack of ER-to-
Golgi trafficking following ER stress (Fig 7A). The Golgi form of
ATF6a was observed for the wild-type protein but not the [D564G]
mutant following DTT activation in the presence of the S1P inhibitor
(Fig 7A, lanes 2 and 4). When the [D564G] mutant was stably
expressed in the ERp18 KO cells, no ATF6-P cleavage product was
observed in either the membrane or nuclear fraction (Fig 7B, lanes
3 and 7). To demonstrate that this mutant can be cleaved by S1P
and S2P, we treated cells with brefeldin A, which results in the relo-
cation of Golgi proteins to the ER (Niu et al, 2005). Under these
conditions, cleavage of the [D564G] mutant of ATF6a in both wild-
type and ERp18 KO cells was observed as evidenced by the appear-
ance of cleavage products in the membrane and nuclear fractions
(Fig 7B, lanes 2 and 4, and lanes 6 and 8). These results indicate
that the ATF6-P cleavage product seen for wild-type ATF6a in the
ERp18 KO cell line is generated following trafficking from the ER. In
A B
Figure 7. ATF6a cleavage occurs in a post-ER compartment.
A HEK293T cells stably overexpressing wild-type ATF6a or a D564G mutant were treated with 10 mM DTT as indicated to induce ER stress in the presence of the S1P
inhibitor. Cell lysates were prepared, separated by SDS–PAGE, and then probed with anti-ATF6a. Blot reveals the presence of O-linked glycan-modified
Golgi-translocated ATF6 (designated G), which is absent for the D564G mutant, confirming a lack of ER-to-Golgi trafficking.
B Wild-type and ERp18 KO cell lines stably expressing ATF6a D564G were either left untreated () or treated (+) with 5 lg/ml brefeldin A for 1 h prior to cell lysis. The
anti-ATF6a Western blot of membrane fractions reveals proteolytic processing by S1P to produce ATF6-M, only in the brefeldin A-treated cells. Nuclear fractions
confirm the presence of S2P cleavage product, ATF6-N, following brefeldin A treatment. Anti-HDAC2 was used as a loading control for the nuclear fraction.
Source data are available online for this figure.
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addition, it demonstrates that S1P is fully functional in the ERp18
KO cell line.
ERp18 KO leads to accelerated trafficking from the ER to
the Golgi
The fact that ATF6a is cleaved in the Golgi in the absence of ER
stress in the ERp18 KO cells would suggest that ERp18 has a role in
retention. To address this point, we investigated whether there is
any change to the kinetics of trafficking of ATF6a from the ER to the
Golgi following ER stress. We followed trafficking after ER stress
activation with DTT as this causes a rapid activation of ATF6a
allowing the kinetics of transport to be evaluated. Trafficking was
monitored by the appearance of Golgi-modified ATF6a in the pres-
ence of the S1P inhibitor (Fig 8). Note that the presence of the S1P
inhibitor leads to the appearance of the ATF6-P cleavage product in
the cell lines stably expressing ATF6a. In wild-type cells, the Golgi
form of ATF6a first appeared at 30 min after DTT treatment with
maximal Golgi form at 45 min (Fig 8A and G). In contrast, in the
ERp18 KO cells most of the Golgi form was apparent after 30 min
before declining at 45 and 60 min (Fig 8B and G). The appearance
of the Golgi form of ATF6a was quantified to illustrate the kinetics
of transport (Fig 8G). The absence of ERp18 led to an enhanced rate
of trafficking, suggesting that ERp18 monitors the exit of ATF6a
from the ER particularly after induction of ER stress. Expression of
ERp18 in the KO cell line reversed the acceleration in ATF6a traf-
ficking following DTT activation (Fig 8C and G). The DTT treatment
may well affect the catalytic activity of ERp18 or the disulfide status
of ATF6a; however, even in the presence of 10 mM DTT, ERp18
slows the exit of ATF6a from the ER. Taken together with the aber-
rant post-ER cleavage of ATF6a in the ERp18 KO cells, these results
suggest that the role of ERp18 is to prevent the premature trafficking
of forms of ATF6a that are poor substrates for S1P.
The role of ERp18 in retention of ATF6a could be related to the
reduction of intra- or interchain disulfides within the lumenal
domain. To evaluate this possibility, we determined the effect of
mutating one or both of the cysteines within the ATF6a lumenal
domain on the kinetics of transport (Fig 8D–G). For this experiment,
we transiently expressed the ATF6 constructs in HEK293T cells, an
approach which did not give rise to the ATF6-P product even in the
presence of the S1P inhibitor. Note that the single cysteine mutants
are still able to form interchain disulfides (Fig 4) whereas the
double mutant cannot form any disulfides. For both the single
mutants, the amount of ATF6a reaching the Golgi increased
throughout the time course (Fig 8D and E). Very little of the double
cysteine mutant was trafficked to the Golgi (Fig 8F), possibly due to
a lack of correct folding. There was no evidence of a more rapid exit
of ATF6a from the ER at early time points for any of the cysteine
mutants as seen for the wild-type protein in the ERp18 KO cells.
These results along with a lack of rapid trafficking in the presence
of DTT indicate that the retention caused by the presence of ERp18
is not dependent on disulfide reduction.
Discussion
The activation of ATF6a during the UPR is a highly regulated process
requiring the release of ER retention and subsequent trafficking to
the Golgi apparatus. For trafficking to occur, proteins involved in
retention dissociate, disulfides within the lumenal domain are
reduced, ATF6a oligomers dissociate, and reduced monomeric
ATF6a is packaged into COPII-coated vesicles for transport out of the
ER (Fig 9; Nadanaka et al, 2007; Schindler & Schekman, 2009). The
initial trigger for release comes from either unfolded proteins (Ye
et al, 2000) or alterations to the lipid composition of the ER
membrane (Tam et al, 2018). BiP is known to dissociate from ATF6a
in the presence of unfolded proteins (Shen et al, 2002), which could
potentially lead to the trafficking of disulfide-bonded ATF6a to the
Golgi. In this work, we demonstrate a role for the oxidoreductase
ERp18 in binding to ATF6a following ER stress. In ERp18 KO cells,
ATF6a is trafficked more rapidly to the Golgi, suggesting it acts to
retain ATF6a in the ER following BiP release. In addition, in the
absence of ERp18 a fraction of ATF6a is cleaved by a post-ER-loca-
lized protease, distinct from S1P, resulting in a product (ATF-P) that
accumulates and is not cleaved by S2P. To facilitate ER retention,
ERp18 may bind to and mask previously identified Golgi-localization
sequences within the ATF6a lumenal domain (Shen et al, 2002) to
prevent trafficking and dissociate to allow loading into COPII vesi-
cles. ERp18 is a disulfide exchange protein (Jeong et al, 2008) and
can form mixed disulfides with ATF6a and so could directly reduce
the disulfides within its lumenal domain thereby triggering its
release. Hence, we have demonstrated that ERp18 performs an
important regulatory role during the UPR, binding to ATF6a follow-
ing BiP release thereby preventing premature exit from the ER.
How the association of BiP with ATF6a is regulated is unclear
but is critical to activate the ATF6a signaling pathway. Previous
work has shown that BiP forms a relatively stable association with
the ATF6a lumenal domain and is unlikely to dissociate simply in
the presence of unfolded proteins (Shen et al, 2005). In addition, an
isolated ATF6a–BiP complex was resistant to dissociation in the
presence of ATP, suggesting the requirement for additional cellular
factors to facilitate release. Finally, using a semi-permeabilized cell
assay that recapitulates vesicular budding and ATF6a exit from the
ER, it was demonstrated that a reducing agent and ATP work syner-
gistically to dissociate the complex (Schindler & Schekman, 2009).
Collectively these studies indicate a requirement for additional
factors to facilitate the release of BiP from ATF6a. BiP has been
shown previously to be modified by the oxidation of thiols to either
become sulfenylated or form a disulfide (Wei et al, 2012; Wang &
Sevier, 2016). The requirement for a reducing agent for BiP dissocia-
tion from ATF6a might indicate the reduction of a thiol-modified
BiP by a member of the PDI family. It is intriguing to consider that
both PDIR (Higa et al, 2014) and ERp18 have been shown to be
associated with ATF6a and required for its activation, strongly
suggesting a role for disulfide exchange in regulating the stability of
the BiP–ATF6a complex.
The reduction of disulfides within ATF6a is a prerequisite for
trafficking from the ER (Nadanaka et al, 2007). We have demon-
strated that this reduction can be carried out by some but not all
members of the PDI family. Formation of mixed disulfides with
substrate-trapping mutants of the PDI enzymes, including ERp18,
indicates their ability to reduce ATF6a under non-stressed condi-
tions, suggesting some redundancy. However, only ERp18 interacts
and forms mixed disulfides with ATF6a under stress conditions,
showing specificity in this stage of activation and trafficking. Hence,
the initial reduction of the BiP–ATF6a complex could be facilitated
ª 2019 The Authors The EMBO Journal e100990 | 2019 11 of 18





Figure 8. Deletion of ERp18 promotes ER-to-Golgi trafficking of ATF6a.
A–C Wild-type cells stably expressing ATF6a (A) or ERp18 KO cells stably expressing ATF6a (B), and ERp18 KO cells stably expressing ATF6a transiently transfected with
ERp18 (RV cells) (C), were pre-treated with 30 lM PF429242 (S1P inhibitor) for 1 h prior to induction of ER stress with 10 mM DTT as indicated.
D–F Wild-type cells transiently expressing ATF6 C467A (D), ATF6 C618A (E), or ATF6 DM (F) were treated as above. Whole-cell lysates were separated by SDS–PAGE under
reducing conditions and analyzed by Western blotting for ATF6a. The positions of unprocessed ER-localized ATF6a (ER) and the O-linked glycan-modified
Golgi-translocated ATF6a (Gol) are indicated as is ATF6-P.
G The percentage of Golgi-ATF6a was quantified, and the error bars represent  standard deviation for at least three independent experiments.
Source data are available online for this figure.
12 of 18 The EMBO Journal e100990 | 2019 ª 2019 The Authors
The EMBO Journal Ojore BV Oka et al
by several members of the PDI family, but only ERp18 acts on
ATF6a following release from BiP. The role of other proteins such
as thrombospondin 4 in this overall process is unclear but could be
to act as cargo receptors for packaging into COPII vesicles (Lynch
et al, 2012).
The observation that ATF6a can be cleaved to ATF6-P in the pres-
ence of an S1P inhibitor has been reported previously, but the signifi-
cance of this event has not been evaluated (Ye et al, 2000; Gallagher
et al, 2016). It is known that the recognition of substrates for S1P is
stringent in that they need to contain the consensus sequence for
cleavage as well as the lumenal domain. Deletion of even a small
portion of the lumenal domain results in a lack of cleavage (Chen
et al, 2002). In addition, efficient cleavage by S1P requires ATF6a to
be in a reduced state with no intra- or interchain disulfides (Nada-
naka et al, 2007). Therefore, the formation of ATF6-P in the absence
of ERp18 indicates a lack of recognition by S1P due to the premature
trafficking of disulfide-bonded ATF6a. Previous studies indicate that
ATF6-P should be a substrate for S2P as most of the lumenal domain
is required to prevent S1P-independent cleavage by S2P (Shen &
Prywes, 2004). The persistence of this product and its lack of cleav-
age to ATF6-N by S2P would suggest that it is trafficked to a post-
Golgi compartment making it inaccessible to S2P.
Studies into the activation of the other UPR sensors, Ire1 and
PERK, have highlighted the complexity of the process, suggesting
multiple layers of regulation including reversible post-translational
modifications as well as co-factors regulating oligomerization,
complex formation, and BiP binding (Carrara et al, 2015; Preissler
et al, 2015; Amin-Wetzel et al, 2017; Hong et al, 2017; Sepulveda
et al, 2018). It is of interest to note that the activation of each UPR
sensor involves the dissociation of BiP; however, the consequence
of BiP dissociation differs: Ire1 and PERK oligomerize to activate
their kinase domains, whereas ATF6a dissociates to form monomers
that can then exit the ER. Hence, for ATF6a there is a specific
requirement for additional factors such as ERp18 to prevent ER exit
following BiP release, thereby ensuring efficient processing to an
active transcription factor.
Figure 9. ERp18 modulates trafficking and cleavage of ATF6a.
Under no stress (light green shading), BiP binds to the lumenal domain of disulfide-bondedmonomer and dimer ATF6a, preventing ER exit (Step 1). In Step 2, under conditions
of ER stress (light red shading), ERp18 or other PDI family members could reduce ATF6a disulfides, resulting in the release of BiP from ATF6a. ERp18 binds, possibly before or
after BiP release, and regulates ER exit. Reduced ATF6a is subsequently packaged into COPII vesicles and transported to the Golgi apparatus (Step 3). The regulated binding and
release of chaperones and oxidoreductases ensures that only reduced ATF6a, which is the optimal substrate for S1P, is transported to the Golgi. Sequential cleavage by S1P
and then S2P leads to membrane release and production of ATF6-N, respectively (Step 4). ATF6-N traffics to the nucleus to transactivate genes required to restore ER
homeostasis. The fate of the lumenal domain is unknown but it maybe secreted. In the absence of ERp18, ATF6a rapidly exits the ER and is cleaved by an unknown post-ER-
localized protease to produce a fragment that is inefficiently processed by either S1P or S2P.
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Materials and Methods
Antibodies
The following primary rabbit polyclonal antibodies were used: anti-
PDIR, anti-ERp57, anti-P5, and anti-GRP170 (all from ThermoFisher,
cat. # PA3-007, PA3-009, PA3-008, and PA5-27655, respectively). In
addition, a rabbit polyclonal antibody to the HA-tag (Sigma, cat.
#H6908) and a goat polyclonal antibody to reticulocalbin (Santa
Cruz, cat. #sc-109422) were used. Mouse monoclonal antibodies
used were anti-ATF6 (Abcam, cat. #ab122897), anti-GAPDH (Ther-
moFisher, cat. #AM4300), anti-V5 (Invitrogen, cat. #R960-25), anti-
myc clone 4A6 (Merck, cat. #05-724), anti-HA (Sigma, cat. #H3663),
and anti-BiP (BD Biosciences, cat. #610979). A rabbit monoclonal
anti-HDAC2 was also used (Abcam, cat. #32117). The following
secondary antibodies were used for Western blotting: goat anti-
mouse IRDye 800 (cat. #10751195), goat anti-mouse IRDye 680 (cat.
#A32729), goat anti-rabbit IRDye 800 (cat. #13477187), and goat
anti-rabbit IRDye 680 (cat. #35568, all from ThermoFisher).
Secondary antibodies for immunofluorescence were sheep anti-
rabbit-FITC (Sigma, cat. #F7512) and donkey anti-mouse-Texas Red
(Abcam, cat. #ab6818).
Cell lines
All HEK293T and HT1080 cells were maintained in DMEM supple-
mented with 10% FBS and 100 units/ml penicillin and 100 lg/ml
streptomycin at 37°C in a 5% CO2 incubator.
DNA constructs
The pCGN-ATF6 plasmid containing an N-terminal HA epitope was
obtained from Adam Benham (Durham University), originally a gift
from Ron Prywes (Zhu et al, 1997). This construct was used as
template to produce an ATF6a fragment containing an N-terminal
HA-tag and a C-terminal V5-tag followed by a KDEL sequence and
stop codon, using a two-step PCR with appropriate primers
(Table EV1). This DNA fragment was then cloned into the NheI and
NotI sites of pcDNA3.1. The single (ATF6a C467A and ATF6a
C618A) and double (C467A/C618A, ATF6a DM) cysteine-to-alanine
mutations in the lumenal domain of ATF6 were generated using the
QuikChange site-directed mutagenesis kit (Agilent) with the appro-
priate primer pairs (Table EV1). The ATF6a S1P mutant R415A/
R416A was synthesized by GenScript. The human PDI CXXA trap
mutants have been described previously (Jessop et al, 2009; Oka
et al, 2013). Briefly, the coding sequences including a C-terminal
V5-epitope tag followed by a KDEL sequence and a stop codon were
amplified by PCR and then cloned into pcDNA3.1. The human
TMX1 CXXA trap mutant containing cysteine-to-alanine mutation in
the active site and a C-terminal HA-tag, cloned into pcDNA3.1(+)
vector (Pisoni et al, 2015), was a gift from Maurizio Molinari (IRB,
Bellinzona, Switzerland).
The wild-type EGFP-tagged human ATF6a S1P (R415A/R416A)
was obtained from Addgene (Chen et al, 2002). The ATF6a mutant
was cloned into pEGFP-C3 vector to allow expression of a fusion
protein containing an N-terminal EGFP protein. The EGFP-ATF6-S1P
C618A mutation was generated using the QuikChange site-directed
mutagenesis kit (Agilent) with the appropriate primer pairs
(Table EV1). The wild-type human reticulocalbin 1 (RCN1) cloned
into the pCAGGS vector was a kind gift from Masayuki Ozawa,
Kagoshima University, Japan (Ozawa and Muramatsu, 1993).
Cell culture and transfections
HEK293T cells were transfected with plasmid DNA at 80–90% con-
fluence using either MegaTran (OriGene) or Lipofectamine 2000
(ThermoFisher Scientific) transfection reagent. To generate stable
cell lines, the transfected cells were placed on antibiotic selection
for approximately 2–4 weeks until colonies appeared. Positive
clones were identified by Western blotting.
Cell lysis, immunoisolation, and Western blots
Cells were harvested by treatment with trypsin–EDTA (Gibco) or by
scrapping using a rubber policeman (Greiner Bio-One). They were
collected by centrifugation at 1,000 × g for 5 min and then washed
twice by ice-cold PBS. The cells were then resuspended in lysis
buffer [1% (v/v) Triton X-100, 50 mM Tris–HCl (pH 7.4), 150 mM
NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), and 0.5 mM
phenylmethylsulfonyl fluoride (PMSF)], incubated on ice for
10 min, followed by centrifugation at 16,000 × g to obtain the post-
nuclear supernatant.
Prior to immunoisolation, the post-nuclear supernatant was
precleared by incubating with protein A Sepharose beads (Generon)
for 30 min at 4°C. The mixture was then precleared by centrifuga-
tion at 14,000 × g for 1 min and the supernatant incubated with
protein A Sepharose beads and the appropriate antibody or GFP-
Trap (Chromotek, cat. #ABIN509407) for 16 h at 4°C. Immunoiso-
lated material was washed three times in lysis buffer or in SDS wash
buffer (lysis buffer supplemented with 350 mM NaCl and 0.5%
SDS) for the GFP-Trap isolations. Samples were boiled at 95°C for
5 min in SDS–PAGE sample buffer [200 mM Tris–Cl (pH 6.8), 3%
SDS, 10% glycerol, 1 mM EDTA, and 0.004% bromphenol blue]
prior to SDS–PAGE under either reducing (treated with 50 mM
DTT) or non-reducing conditions.
For Western blotting, proteins were transferred to nitrocellulose
membrane (Li-Cor Biosciences), which were blocked in 5% (w/v)
non-fat dried skimmed milk in TBST [Tris-buffered saline with
Tween-20: 10 mM Tris, 150 mM NaCl (pH 7.5), and 0.1% (v/v)
Tween-20] for 60 min. Primary antibodies were diluted in TBST,
and incubations were carried out for 16 h at either 4°C or room
temperature. IRDye fluorescent secondary antibodies were used for
detection, typically at 1:5,000 dilutions. Blots were scanned using
an Odyssey SA imaging system (Li-Cor Biosciences).
Mass spectrometry
Confluent untransfected HEK293T and HEK293T cells stably
expressing HA-ATF6-V5 were either left untreated or treated with
5 lg thapsigargin for 60 min. The cells were then treated with
2 mM dithiobis(succinimidyl propionate; DSP) and incubated at
room temperature for 30 min to form protein cross-links followed
by 20 mM Tris (pH 7.5) for 15 min at room temperature to quench
the reaction. The cells were collected by centrifugation at 1,000 × g
for 5 min and then rinsed twice with ice-cold PBS supplemented
with 20 mM NEM. Post-nuclear supernatant was prepared in lysis
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buffer containing 1% (v/v) Triton X-100, 50 mM Tris–HCl (pH 7.4),
150 mM NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), and
0.5 mM phenylmethylsulfonyl fluoride (PMSF) supplemented with
EDTA-free protease inhibitor tablet.
Cell lysates were precleared by incubation with protein A
Sepharose (PAS) for 30 min at 4°C, before incubation with anti-
V5-conjugated agarose beads (Sigma) for 16 h at 4°C. The beads
were washed three times with lysis buffer supplemented with
0.5% SDS and then incubated with 10 mM DTT (prepared in
25 mM ammonium bicarbonate) for 10 min to elute cross-linked
complexes. Trypsin (0.3 ll, 0.2 ng/ll, Promega, sequencing grade)
was added to the protein mixture and the solution incubated at
37°C overnight, to allow complete digestion. A portion of the
resultant peptides were then injected on an Acclaim PepMap 100
C18 trap and an Acclaim PepMap RSLC C18 column (Thermo-
Fisher Scientific), using a NanoLC Ultra 2D Plus loading pump and
a NanoLC AS-2 autosampler (Eksigent). The peptides were held on
the trap and washed for 20 min and were eluted with a gradient
of increasing acetonitrile, containing 0.1% formic acid (2–20%
acetonitrile in 90 min, 20–40% in a further 30 min, followed by
98% acetonitrile to clean the column, before re-equilibration to
2% acetonitrile). The eluate was sprayed into a TripleTOF
5600 + electrospray tandem mass spectrometer (AB Sciex, Foster
City, CA) and analyzed in Information Dependent Acquisition
(IDA) mode, performing 250 ms of MS followed by 100 ms of MS/
MS analyses on the 20 most intense peaks seen by MS. The MS/
MS data file generated via the “Create mgf file” script in PeakView
(Sciex) was analyzed using the Mascot search algorithm (Matrix
Science), against the NCBInr database (August 2016) considering
both all species (93482448 sequences) and restricting the search to
Homo sapiens (331464 sequences), trypsin as the cleavage enzyme
and N-ethylmaleimide, hydrolyzed N-ethylmaleimide modifications
of cysteine, thioacyl modification of lysines and N-termini, and
methionine oxidation all as variable modifications. The peptide
mass tolerance was set to 20 ppm and the MS/MS mass tolerance
to 0.05 Da. A protein was accepted as identified if it had 2 or
more peptides with Mascot Ion Scores above the identity threshold
(P < 0.05), and for those proteins identified by only two peptides,
the MS/MS spectral assignments match most of the peaks in the
MS/MS spectra.
For MS analyses of gel bands, the gel band was excised and cut
into 1-mm cubes. These were then subjected to in-gel digestion,
using a ProGest Investigator in-gel digestion robot (Genomic Solu-
tions, Ann Arbor, MI) using standard protocols (Shevchenko et al,
1996). Briefly, the gel cubes were destained by washing with a 1:1
mixture of 30 mM potassium ferricyanide and 100 mM sodium thio-
sulfate and subjected to reduction and alkylation before digestion
with trypsin at 37°C. The peptides were extracted with 10% formic
acid and concentrated down to 20 ll using a SpeedVac (Thermo
Savant). A portion of the resultant peptides were then injected on
an Acclaim PepMap 100 C18 trap and an Acclaim PepMap RSLC
C18 column (ThermoFisher Scientific), using a NanoLC Ultra 2D
Plus loading pump and a NanoLC AS-2 autosampler (Eksigent). The
peptides were eluted with a gradient of increasing acetonitrile,
containing 0.1% formic acid (5–40% acetonitrile in 5 min, 40–95%
in a further 1 min, followed by 95% acetonitrile to clean the
column, before re-equilibration to 5% acetonitrile). The eluate was
sprayed into a TripleTOF 5600 + electrospray tandem mass
spectrometer (AB Sciex) and analyzed in Information Dependent
Acquisition (IDA) mode, performing 250 ms of MS followed by
100 ms of MS/MS analyses on the 20 most intense peaks seen by
MS. The MS/MS data file generated via the “Create mgf file” script
in PeakView (Sciex) was analyzed using the Mascot search algo-
rithm (Matrix Science), against the NCBInr database (August 2016)
considering both all species (93482448 sequences) and restricting
the search to Homo sapiens (331464 sequences), trypsin as the
cleavage enzyme and N-ethylmaleimide, hydrolyzed N-ethylmalei-
mide modifications of cysteine, thioacyl modification of lysines and
N-termini, and methionine oxidation all as variable modifications.
The peptide mass tolerance was set to 20 ppm and the MS/MS mass
tolerance to 0.05 Da.
Analyses of ATF6–PDI mixed-disulfide complexes
HEK293T cells were co-transfected with ATF6a or its cysteine
mutants and PDI CXXA trap mutants. After 24 h following transfec-
tion, cells were either left untreated or treated with either 5 lM
thapsigargin, 5 lg/ml tunicamycin, or 20 lM MG132 for 1 h prior
to cell lysis, immunoisolation, and Western blotting.
Silver staining
HEK293T cells were transiently transfected with either EGFP-ATF6
or EGFP-ATF6 S1P only or co-transfected with ERp18 substrate-trap-
ping mutant. Whole-cell lysates were prepared 24 h after transfec-
tion and GFP-ATF6 immunoisolated as described above.
Immunoisolated material was separated by SDS–PAGE under
non-reducing conditions and bands detected by silver staining
(Gharahdaghi et al, 1999).
CRISPR/Cas9-based knockout of ERp18
The single guide RNA (gRNA) matching the genomic targets was
designed using the CRISPR Design Tool—nickase analysis
(crispr.mit.edu). The CRISPR/Cas9 expression vectors were
prepared as reported previously (Kabadi et al, 2014). Briefly, single
gRNAs were engineered with compatible overhangs (Table EV1),
annealed, and phosphorylated before cloning into BbsI sites of
compatible expression vectors. sgRNA_14 was cloned into the mU6
vector, while sgRNA_8 and sgRNA_10 were cloned into the hU6
vector. The integrity of the constructs was confirmed by DNA
sequencing. Two sgRNAs, selected based on the nickase analysis,
were combined, as indicated below, and then cloned into the
pMulti-Cas9D10A-GFP vector using Golden Gate Assembly.
1 sgRNA_14 and sgRNA_8
2 sgRNA_14 and sgRNA_10
To generate an ERp18 knockout, 5.5 lg of the individual pMulti-
Cas9D10A-GFP vectors was co-transfected with 0.5 lg pPur (puro-
mycin-resistant vector; Clontech) into HEK293T cells stably express-
ing ATF6. After 24-h incubation in media, cells were transferred to
media supplemented with 1 lg/ml puromycin and incubated for a
further for 5 days, then subsequently in media without puromycin
until colonies appeared (about 12 days later). Positive ERp18 knock-
out cells were identified by Western blotting using the mouse anti-
ERp18.
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RNA extraction and qPCR
Total RNA was extracted from confluent cells from 6-cm dishes
either untreated or treated with 1 lM thapsigargin for 16 h using
the RNeasy Mini Kit (Qiagen) according to the manufacturer’s
instructions. cDNA synthesis was carried out using the SuperScript
II Reverse Transcriptase Kit (Invitrogen) according to the manufac-
turer’s protocols. Quantitative real-time PCR was carried out with
500 ng cDNA using the Brilliant III Ultra-Fast SYBR Green qRT-PCR
Master Mix (Agilent Technologies) in a StepOnePlus system
(Applied Biosystems). The primer pairs used are detailed in
Table EV1.
Analyses of ATF6a transcriptional targets in ERp18 knockout cells
Wild-type and ERp18 KO HEK293T cell lines stably overexpressing
recombinant ATF6 wild type were used. To generate the ERp18 KO
reversion (18KO RV) cell line, the ERp18 KO HEK/ATF6 cells were
transiently transfected with a pcDNA3/ERp18 plasmid (Jessop et al,
2009). Confluent cells were either left untreated or treated with
1 lM thapsigargin for 16 h. Whole-cell lysates were separated by
SDS–PAGE under reducing conditions followed by Western blotting.
Quantification of band intensities was carried out with the Li-Cor
Image Studio version 4 software and histograms prepared using
Origin 6.0 professional software.
ER stress-induced cleavage of ATF6a
Wild-type or ERp18 knockout HEK293T cells overexpressing ATF6a
were either left untreated () or treated (+) for 1 h with 30 lM
PF429242 (S1P inhibitor) before addition of 10 mM DTT or 5 lM
thapsigargin to induce ER stress. For the brefeldin A (5 lg/ml) treat-
ment, cells were incubated with the drug for 1 h prior to cell lysis.
Post-treatment, cells were harvested and subjected to differential
centrifugation as described previously (Gallagher et al, 2016).
Briefly, cells were washed once with 3 ml PBS supplemented with
EDTA-free protease inhibitor tablet. Cells were then scraped off the
dish in 2.9 ml ice-cold PBS, using a rubber policeman (cell scraper)
into a 15-ml tube. Samples were centrifuged at 3,000 × g for 5 min,
and supernatant was removed. Cells were resuspended in 1 ml ice-
cold buffer A [10 mM HEPES (pH 7.4), 250 mM sucrose, 10 mM
KCl, 1.5 mM MgCl2, 1 mM EDTA, and 1 mM EGTA] supplemented
with protease inhibitor, transferred to 1.5-ml tube, and left on ice for
10 min. Cells were lysed by passing through a 23-gauge needle
attached to a 1-ml syringe, 20 times, followed by centrifugation at
1,000 × g for 7 min at 4°C to obtain the nuclear pellet; the super-
natant contains the cytosolic and membrane components. The pellet
was washed once in 500 ll buffer A (plus protease inhibitor) and
then centrifuged at 1,000 × g for 7 min at 4°C. The pellet was then
resuspended in 100 ll buffer B [10 mM HEPES (pH 7.6), 2.5% glyc-
erol, 420 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, and 1 mM EGTA]
supplemented with protease inhibitor, followed by incubation for
60 min at 4°C. The samples were centrifuged at 100,000 × g for
30 min at 4°C to obtain a supernatant containing the nuclear extract.
To obtain the membrane components, the supernatant from the
initial 1,000 × g centrifugation was centrifuged at 100,000 × g for
30 min at 4°C. The pellet obtained was resuspended in 100 ll buffer
B (+protease inhibitor). The nuclear extract and membrane fractions
were separated by SDS–PAGE under reducing conditions and ATF6
identified by Western blotting.
ER-to-Golgi trafficking of ATF6a
Wild-type, ERp18 KO, and 18KO RV HEK293T/ATF6 wild-type cells
were used to follow ER-to-Golgi trafficking. The individual ATF6a
cysteine mutants were transiently transfected into HEK293T cells.
Confluent cells were pre-treated with 30 lM PF429242 (S1P inhi-
bitor) for 60 min prior to inducing ER stress with 10 mM DTT.
Whole-cell lysates were separated by SDS–PAGE under reducing
conditions and ATF6 identified by Western blotting as described
above. Quantification of band intensities was carried out with the
Li-Cor Image Studio version 4 software and histograms prepared
using Origin 6.0 professional software.
Metabolic labeling and pulse-chase analysis
Wild-type and ERp18 KO HEK293T cells stably overexpressing
ATF6 were incubated in medium lacking methionine and
cysteine for 30 min and pulse-labeled for 30 min with 22 lCi/ml
of EXPRESS35S Protein Labeling Mix (PerkinElmer). The cells
were rinsed twice in PBS to remove the radiolabel and then
incubated in complete medium to initiate the chase periods.
Subsequently, cells were washed twice with PBS supplemented
with 20 mM NEM and lysed in cell lysis buffer containing
20 mM NEM. Samples were subject to centrifugation at
16,000 × g at 4°C to obtain the post-nuclear supernatant. ATF6a
immunoisolation was carried out as described above using anti-
ATF6 (Abcam). Samples were separated under non-reducing and
reducing SDS–PAGE gels, fixed, dried, and exposed to a phos-
phorimager plate for 72 h. Radioactivity was detected using a
Fujifilm FLA-7000 Phosphorimager.
Expanded View for this article is available online.
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